Lilly(US:LLY) Xin Lang Cai Jing·2025-12-11 14:10Group 1 - The core point of the article is that Eli Lilly's new weight loss drug, retatrutide, has shown significant weight loss results and pain relief in a late-stage clinical trial [1][4] - In the 68th week of the trial, participants lost an average of 71.2 pounds (approximately 32.3 kilograms) and experienced substantial relief from osteoarthritis-related pain [1][4] - Eli Lilly's stock rose by 1.5% in pre-market trading, indicating positive market sentiment towards the drug [2][4] Group 2 - Retatrutide is a key focus for Eli Lilly in the next-generation weight loss drug market, which includes other successful drugs like tirzepatide (brand name: Mounjaro) and zepatier (brand name: Zybond) [2][4] - Eli Lilly has surpassed Novo Nordisk to become the leader in the GLP-1 drug market, with a market capitalization exceeding $1 trillion [2][4] - The company is expanding its research into next-generation weight loss drugs, aiming to enhance drug efficacy and accessibility for a broader range of conditions [2][4] Group 3 - Unlike other weight loss drugs that target one or two hunger-related hormone receptors, retatrutide can block three related receptors simultaneously [3][5] - Eli Lilly anticipates that seven additional Phase III clinical trials for retatrutide will be completed by 2026, assessing its impact on various conditions including sleep apnea, chronic lower back pain, and metabolic dysfunction-related fatty liver disease [3][5] - The president of Eli Lilly's cardiovascular and metabolic health division, Kenneth Castor, stated that retatrutide is expected to be an important treatment option for patients with significant weight loss needs and specific comorbidities, including knee osteoarthritis [3][5]